ArticleActa neurochirurgica2021
Prevalence and outcome of comorbidities associated with acromegaly.
Article in Acta neurochirurgica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Consensus on acromegaly complications: an update.Pituitary · 2026Article
- Growth Hormone-Secreting Pituitary Macroadenoma: Diagnosis of Acromegaly in a Young Adult.Cureus · 2025Article
- Prevalence and evolution of hypertension in a large Iberian cohort of patients with acromegaly.Pituitary · 2025Article
- Craniofacial parameters and obstructive sleep apnea in newly diagnosed acromegaly.Frontiers in endocrinology · 2025Observational
- Is diabetes with acromegaly for life?Pituitary · 2024Article
- The Effect of Metformin Treatment on Disease Control in Patients with Acromegaly.Endocrine, metabolic & immune disorders drug targets · 2024Article
- Secondary diabetes mellitus in acromegaly.Endocrine · 2023Review
- Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing's syndrome, acromegaly and neuroendocrine tumours.Frontiers in endocrinology · 2023Review
- Clinical Biology of the Pituitary Adenoma.Endocrine reviews · 2022Review
- A New Device for Remote Monitoring of Vital Parameters in Acromegalic Patients: Pilot Study.Endocrine, metabolic & immune disorders drug targets · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcromegaly is associated with various comorbidities, such as arterial hypertension (aHT), type 2 diabetes mellitus (DM2), obstructive sleep apnoea syndrome (OSAS), carpal tunnel syndrome (CTS) and polyposis coli. For therapeutic decisions, it is essential to know if, and to what extent, these associated morbidities are reversible or preventable. The aim of this study is to assess the prevalence and course of aHT, obesity, OSAS, CTS, DM2 and polyposis coli in acromegalic patients.
methodsThe following criteria for inclusion in this database study were used: treatment for acromegaly at the authors' institutions; full endocrinological and radiological work- and follow-up; screening for aHT, DM2, CTS, OSAS, obesity and polyposis coli. All patients were followed-up for > 3 months, and treatments were indicated with the intent of biochemical remission (normal IGF-1 and random growth hormone level).
resultsSixty-three patients were included. Twelve (19%), 45 (71%) and 6 (10%) patients harboured micro-, macro- and giant adenomas, respectively. Nineteen tumours (30%) invaded the cavernous sinus. Mean tumour volume was 5.4 cm
conclusionsTreating acromegaly may relieve threatening associated morbidities such as aHT and DM2; nevertheless, only few comorbidities are reversible, which highlights the importance of treating acromegaly as early as possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.